| [1] |
Liu W, Chen Q, Xia YM. New mechanistic insights of melasma[J]. Clin Cosmet Investig Dermatol, 2023, 16: 429-42. doi:10.2147/CCID.S396272
|
| [2] |
Dias MO, Minagawa FH, Teixeira de Abreu AF, et al. Prevalence of facial melasma among adult women in a multiracial population[J]. Int J Dermatol, 2024, 63(4): e89-91. doi:10.1111/ijd.17078
|
| [3] |
Piętowska Z, Nowicka D, Szepietowski JC. Understanding melasma-how can pharmacology and cosmetology procedures and prevention help to achieve optimal treatment results? a narrative review[J]. Int J Environ Res Public Health, 2022, 19(19): 12084. doi:10.3390/ijerph191912084
|
| [4] |
Jiryis B, Toledano O, Avitan-Hersh E, et al. Management of melasma: laser and other therapies-review study[J]. J Clin Med, 2024, 13(5): 1468. doi:10.3390/jcm13051468
|
| [5] |
Lee YS, Lee YJ, Lee JM, et al. The low-fluence Q-switched Nd: YAG laser treatment for melasma: a systematic review[J]. Medicina, 2022, 58(7): 936. doi:10.3390/medicina58070936
|
| [6] |
Micek I, Pawlaczyk M, Kroma A, et al. Treatment of melasma with a low-fluence 1064 nm Q-switched Nd: YAG laser: Laser toning in Caucasian women[J]. Lasers Surg Med, 2022, 54(3): 366-73. doi:10.1002/lsm.23474
|
| [7] |
Bosseila M, Ghonim N, Mostafa P. Efficacy and safety of different low fluences of Q-switched Nd: YAG laser in treatment of melasma: a split-face clinical and dermoscopic comparative study[J]. Lasers Med Sci, 2022, 37(1): 675-80. doi:10.1007/s10103-020-03210-z
|
| [8] |
Gao YL, Jia XX, Wang M, et al. Melanocyte activation and skin barrier disruption induced in melasma patients after 1064 nm Nd: YAG laser treatment[J]. Lasers Med Sci, 2019, 34(4): 767-71. doi:10.1007/s10103-018-2658-7
|
| [9] |
胡 婷, 曹永红, 翟 斐, 等. 吡格列酮二甲双胍片联合甘精胰岛素治疗2型糖尿病患者的疗效研究[J]. 成都医学院学报, 2024, 19(6): 1065-9.
|
| [10] |
Pantazopoulos D, Papachristou S, Gouveri E, et al. Metformin: old drug, new therapeutic potential in the skin? a brief narrative review[J]. Adv Ther, 2025, 42(8): 3606-20. doi:10.1007/s12325-025-03256-x
|
| [11] |
Liu X, Sun XJ, Liu YY, et al. Metformin inhibits melanin synthesis and melanosome transfer through the cAMP pathway[J]. Sci Rep, 2025, 15(1): 11442. doi:10.1038/s41598-025-95245-x
|
| [12] |
Banavase Channakeshavaiah R, Andanooru Chandrappa NK. Topical metformin in the treatment of melasma: a preliminary clinical trial[J]. J Cosmet Dermatol, 2020, 19(5): 1161-4. doi:10.1111/jocd.13145
|
| [13] |
Miao MS, Fu ZN, Cao LH. Specification for preparation of chloasma animal model (draft)[J]. Chinese Materia Medica and Clinical Pharmacology, 2017, 28(5): 649-653.
|
| [14] |
武晏屹, 田 硕, 苗 明三. 基于数据挖掘的黄褐斑动物模型应用分析[J]. 中国比较医学杂志, 2020, 30(8): 70-5. doi:10.3969/j.issn.1671-7856.2020.08.011
|
| [15] |
Neris RLS, Dobles AMC, Gomes AV. Western blotting using in-gel protein labeling as a normalization control: advantages of stain-free technology[J]. Methods Mol Biol, 2021, 2261: 443-56. doi:10.1007/978-1-0716-1186-9_28
|
| [16] |
Dong JY, Yao SS, Wu S, et al. Melanogenesis inhibition and anti-inflammation is essential for pigment-clearance in melasma treated by low-fluence Q-switched Nd: YAG 1064 nm laser[J]. Lasers Med Sci, 2025, 40(1): 457. doi:10.1007/s10103-025-04702-6
|
| [17] |
Afshar K, Adibfard S, Nikbakht MH, et al. A systematic review on clinical evidence for topical metformin: old medication with new application[J]. Health Sci Rep, 2024, 7(12): e70281. doi:10.1002/hsr2.70281
|
| [18] |
Wang WZ, Sun XJ, Liu YY, et al. Establishment and validation of a C57BL/6J mouse model for melasma[J]. Cell Prolif, 2025: e70078. doi:10.1111/cpr.70078
|
| [19] |
Morgado-Carrasco D, Piquero-Casals J, Granger C, et al. Melasma: The need for tailored photoprotection to improve clinical outcomes[J]. Photodermatol Photoimmunol Photomed, 2022, 38(6): 515-21. doi:10.1111/phpp.12783
|
| [20] |
Serre C, Busuttil V, Botto JM. Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation[J]. Int J Cosmet Sci, 2018, 40(4): 328-47. doi:10.1111/ics.12466
|
| [21] |
Passeron T, Picardo M. Melasma, a photoaging disorder[J]. Pigment Cell Melanoma Res, 2018, 31(4): 461-5. doi:10.1111/pcmr.12684
|
| [22] |
Nguyen NT, Fisher DE. MITF and UV responses in skin: From pigmentation to addiction[J]. Pigment Cell Melanoma Res, 2019, 32(2): 224-36. doi:10.1111/pcmr.12726
|
| [23] |
Espósito ACC, Brianezi G, de Souza NP, et al. Exploring pathways for sustained melanogenesis in facial melasma: an immuno-fluorescence study[J]. Int J Cosmet Sci, 2018, 40(4): 420-4. doi:10.1111/ics.12468
|
| [24] |
El Ashkar WA, Khaled H, Abdou A. Evaluation of glutathione peroxidase enzyme in patients with melasma: a clinical and immunohistochemical study[J]. Menoufia Med J, 2022, 35(2): 445. doi:10.4103/mmj.mmj_183_21
|
| [25] |
Goandal NF, Rungby J, Karmisholt KE. The role of sex hormones in the pathogenesis of melasma[J]. Ugeskr Laeger, 2022, 184(6): V10210769.
|
| [26] |
Filoni A, Mariano M, Cameli N. Melasma: How hormones can modulate skin pigmentation[J]. J Cosmet Dermatol, 2019, 18(2): 458-63. doi:10.1111/jocd.12877
|
| [27] |
Passeron T, Genedy R, Salah L, et al. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology[J]. J Eur Acad Dermatol Venereol, 2019, 33(6): 987-1005. doi:10.1111/jdv.15497
|
| [28] |
Hai L, Phuong B, Ha L, et al. Dual toning method with the combination of picosecond and microsecond Nd: YAG in refractory melasma unresponsive to picosecond alone[J]. J Cutan Aesthet Surg, 2021, 14(1): 101-6. doi:10.4103/JCAS.JCAS_30_20
|
| [29] |
Aurangabadkar SJ. Optimizing Q-switched lasers for melasma and acquired dermal melanoses[J]. Indian J Dermatol Venereol Leprol, 2019, 85(1): 10-7. doi:10.4103/ijdvl.ijdvl_1086_16
|
| [30] |
Feng JY, Huang LP. Comparison of picosecond and nanosecond Nd: YAG 1064-nm lasers in the treatment of melasma: a split-face randomized clinical trial[J]. Plast Reconstr Surg, 2023, 151(4): 772-7. doi:10.1097/prs.0000000000009994
|
| [31] |
Jang HW, Chun SH, Park HC, et al. Comparative study of dual-pulsed 1064 nm Q-switched Nd: YAG laser and single-pulsed 1064 nm Q-switched Nd: YAG laser by using zebrafish model and prospective split-face analysis of facial melasma[J]. J Cosmet Laser Ther, 2017, 19(2): 114-23. doi:10.1080/14764172.2016.1262958
|
| [32] |
Gokalp H, Akkaya AD, Oram Y. Long-term results in low-fluence 1064-nm Q-Switched Nd: YAG laser for melasma: Is it effective?[J]. J Cosmet Dermatol, 2016, 15(4): 420-6. doi:10.1111/jocd.12253
|
| [33] |
Zhou YJ, Li Y, Hamblin MR, et al. Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched Nd: YAG laser for melasma: a randomized, split-face controlled, 2-year follow-up study[J]. Lasers Surg Med, 2024, 56(3): 263-9. doi:10.1002/lsm.23763
|
| [34] |
Lehraiki A, Abbe P, Cerezo M, et al. Inhibition of melanogenesis by the antidiabetic metformin[J]. J Invest Dermatol, 2014, 134(10): 2589-97. doi:10.1038/jid.2014.202
|
| [35] |
Zhao N, Su X, Li H, et al. Schisandrin B inhibits α-melanocyte-stimulating hormone-induced melanogenesis in B16F10 cells via downregulation of MAPK and CREB signaling pathways[J]. Biosci Biotechnol Biochem, 2021, 85(4): 834-841. doi:10.1093/bbb/zbaa100
|